In the 12/21/01 article “Could Microarrays Replace Sequencers? Callida Genomics Thinks So,” Rade Drmanac, the chief scientific officer of Callida, was erroneously referred to as the chief executive officer. Also, Hyseq owns more than the 50 percent share of Callida indicated in the article, and Affymetrix provided an undisclosed sum to the company, not exactly $1.5 million.
In the 2/22/02 issue, the Patent Watch stated that Arcturus’ RiboAmp RNA Amplification Kit sells for a list price of $1,125. This is out of date: Since November 2001, the kit has sold for a list price of $695.